Late-stage venture AI companies in London

We are an end-to-end biotech developing transformational medicines, with technology at our core.Our ambition is to understand human biology in an unprecedented way; discovering therapies that will treat some of life's most devastating diseases. We leverage single-cell and multi-omics measurements directly from patient tissue, functional assays and machine learning to drive disease understanding — from cause to cure.Medicines born from high-resolution biology, machine learning and clinical insights.Our Lab-in-the-Loop seamlessly integrates single-cell analysis, genomics and machine learning. We have developed powerful technologies which we apply to select druggable targets and develop transformational medicines.

• Series unknown
• 133 employees
• Founded 2019

LabGenius Therapeutics ("LabGenius") is a drug discovery company pioneering the discovery of next-generation therapeutic antibodies. The company’s discovery platform, EVATM, integrates several cutting-edge technologies drawn from the fields of artificial intelligence, robotic automation and synthetic biology. While EVATM is both modality and format-agnostic, LabGenius' internal pipeline is focussed on the development of selectivity-enhanced antibodies for the treatment of solid tumours. The company's novel approach is delivering a pipeline of antibody therapeutics with best-in-class killing profiles.

• Series unknown
• 72 employees
• Founded 2012

Image Analysis Group (IAG) is a global imaging CRO and imaging core lab for biotech and pharma sponsors. IAG delivers end-to-end medical imaging services for clinical trials that use imaging to assess drug safety and efficacy, supporting Phase I to Phase IV studies in oncology, rheumatology, orthopedics, obesity, cardiology, hepatology, neurology, and rare disease.What is an imaging CRO? IAG designs and executes the imaging component of a clinical trial - from imaging endpoint strategy through to regulatory submission - using a centralized imaging core lab model.Imaging modalities supported: X-ray, DXA, CT, MRI, DCE-MRI, functional MRI, PET, PET/CT, PET/MR, SPECT, ultrasound, and cardiac safety imaging.Services:• Imaging endpoint strategy and protocol design - imaging biomarkers and scoring systems including RECIST, iRECIST, mRECIST, RANO, Sharp, van der Heijde, RAMRIS, OARSI, Kellgren–Lawrence, and PDFF; feasibility, sample size, and regulatory alignment with FDA, EMA, MHRA, and PMDA• Imaging Charter, Imaging Manual, Imaging Review Charter, and SOPs aligned to ICH-GCP and 21 CFR Part 11• Site qualification, technologist training, positioning kits, and 24/5 multilingual site support• Secure DICOM image collection, transfer, de-identification, technical and protocol QC, and audit trail• Centralized independent radiological review by board-certified radiologists, with chronological, paired, and randomized reading paradigms and third-reader adjudication• Quantitative imaging and AI-based analysis via DYNAMIKATM, IAG's proprietary platform for automated quantification of synovitis, bone marrow edema, erosions, tumor volumetrics, perfusion, diffusion, and liver fat fraction• Regulatory support for IND, IMPD, NDA, BLA, and MAA submissions and FDA Type B and C meetingsISO 27001, ISO 9001, GDPR, HIPAA, and 21 CFR Part 11 compliant. Global operations across the UK, EU, US, and APAC.Contact IAG to scope your next imaging trial: contact@ia-grp.com

• Series unknown
• 54 employees
• Founded 2007

Delivering customer experience insights that matter, making data actionable. We help businesses to learn and adapt faster, driving change from the frontline to the boardroom. Our AI-powered tools ensure everyone has the insights they need to continuously improve customer experiences—because, in the end, experience is everything.

• Series unknown
• 49 employees
• Founded 2020

ReGenerate exists to unleash the full power of purpose-driven business across the UK by showing how businesses can tackle the biggest challenges faced by people and planet. We want to make purpose-driven business the new normal and the most successful. We do this by using research, events and ecosystem mapping to identify the solutions needed to help businesses profitably do good and we work with our network to advocate for change and build government support for purpose driven business. Our 2025 ambition is for the UK to be ranked the best place to start, grow and lead purpose-driven businesses, and their contribution to tackling social and environmental issues is world leading.Click here to view our latest projects: https://www.re-generate.org/issuesFollow us on LinkedIn to keep up to date with the purpose-driven ecosystem!

• Series unknown
• 46 employees
• Founded 2010